Clinical trials: Skin Lesion
Breast Cancer With Bone Metastasis
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
The objective of this study is to assess the clinical benefit of two different dosing schedules of zoledronic acid in patients with metastatic bone lesions from breast cancer who have already been treated with zoledronic acid for…
- Trial name
- NCT00375427
- Testing
- Zoledronic acid
- Where
- Italy
- Volunteers
- 430 people
- Sponsor
- Novartis Pharmaceuticals
Skin Lesion, Skin Abnormalities
Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions
This study is designed as a multi-center, single-blinded, prospective, randomized, study to compare the safety and effectiveness of the CellFX System to the comparator group, Electrodessication for the treatment of SH lesions in…
- Conditions
- Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia
- Trial name
- NCT04539886
- Testing
- CellFX System, Intralesional Electrodesiccation
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pulse Biosciences, Inc.
Angiofibroma of Face, Tuberous Sclerosis
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric…
- Trial name
- NCT03363763
- Testing
- Sirolimus 0.2%, Sirolimus 0.4%
- Where
- 8 sites in United States, China
- Volunteers
- 24 people
- Sponsor
- Aucta Pharmaceuticals, Inc
Hidradenitis Suppurativa
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNRISE (NCT03713632)
- Testing
- Secukinumab
- Where
- 108 sites in United States, Argentina and 30 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Sclerosis, Scleroderma
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin.
- Trial name
- DISTOL-1 (NCT00775463)
- Testing
- treprostinil diethanolamine
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 148 people
- Sponsor
- United Therapeutics
Melanoma
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
The goal of this clinical research study is to learn if the vaccines, gp100(g209-2M), and MAGE-3, when given in combination with resiquimod (R848), can help to stimulate the immune system against melanoma.
- Trial name
- NCT00960752
- Testing
- gp100, R848 gel, MAGE-3
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Melanoma
Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous Lesions
Dermalyzer is a device intended to be used as a decision support system for assessing cutaneous lesions suspected of being melanomas.
- Trial name
- AI-DSMM (NCT05172232)
- Testing
- Dermalyzer
- Where
- 3 sites in Sweden
- Volunteers
- 231 people
- Sponsor
- Linkoeping University
Prostate Cancer, Magnetic Resonance Imaging
Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Prostate biopsies are currently the gold standard for the diagnosis of prostate cancer. Many biopsies, however, are unnecessary or cannot detect significant prostate cancer (PCa).
- Conditions
- Prostate Cancer, Magnetic Resonance Imaging, Target Lesion, Fusion Biopsy
- Trial name
- NCT03044197
- Testing
- MRI/ultrasound transperineal prostate biopsy, transrectal ultrasound-guided prostate biopsy
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Acute Wounds
Efficacy Study of a New Antimicrobial Wound Dressing to Treat Wounds Caused by Curettage and Electrodesiccation
The purpose of this pilot clinical study is to compare healing rates, pain levels, and incidence of wound complications including infection with the use of a moist PROCELLERA™ Antimicrobial Wound Dressing when compared to a…
- Trial name
- NCT00816101
- Testing
- Procellera™ Antimicrobial Dressing, Mepilex® Border Lite, Adhesive Bandage
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Vomaris Innovations
Pigmented Skin Lesion
Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions
This study is being conducted to evaluate the safety and efficacy of a fractional diode laser for treatment of pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sunspots), and ephelides…
- Trial name
- NCT04202419
- Testing
- FRAX 1940 nm laser
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Psoriasis
Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis
The purpose of this study is to determine whether MOL4239 is effective in adult subjects with mild to moderate plaque psoriasis by comparing two target lesions in which each subject will apply MOL4239 ointment to one target…
- Trial name
- NCT01826201
- Testing
- MOL4239
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Moleculin, LLC
Papulopustular Rosacea
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-1 (NCT05296629)
- Testing
- DFD-29, Doxycycline
- Where
- 27 sites in United States
- Volunteers
- 323 people
- Sponsor
- Journey Medical Corporation
Skin Infections, Bacterial
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA.
- Trial name
- NCT00852540
- Testing
- Retpamulin Ointment, 1%, Linezolid
- Where
- 53 sites in United States
- Volunteers
- 410 people
- Sponsor
- Stiefel, a GSK Company
Breast Cancer Nos Metastatic Recurrent
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
Phase II, randomized, safety and efficacy study in recurrent/metastatic breast cancer with accessible lesions. Primary End point is rate of Progression Free Survival (PFS) at the 16 week treatment time point.
- Trial name
- NCT01703754
- Testing
- Ad-RTS-hIL-12 and Veledimex, Palifosfamide
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Skin Lesion, Skin Abnormalities
Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
This prospective, open label, muti-center study evaluates the use of Nano-Pulse Stimulation (NPS) in the treatment of Sebaceous Hyperplasia (SH) lesions less than 2.5mm in size.
- Conditions
- Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia
- Trial name
- NCT03612570
- Testing
- Nano-Pulse Stimulation Device
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Pulse Biosciences, Inc.
Moderate to Severe Palmoplantar Psoriasis
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Purpose of the study was to demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of secukinumab.
- Trial name
- GESTURE (NCT01806597)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Old World Cutaneous Leishmaniasis
A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis
This Phase 2 study is to determine whether WR279396 with occlusion (a polyurethane dressing) is more effective than WR279396 without occlusion for once daily treatment.
- Trial name
- NCT01536795
- Testing
- WR279,396 with Tegaderm Dressing, WR 279,396 with Gauze and Tape Dressing
- Where
- Tunisia
- Volunteers
- 48 people
- Sponsor
- U.S. Army Medical Research and Development Command
Breast Neoplasm, Lesion
Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery
This pilot clinical trial studies radiofrequency technology in locating non-palpable breast lesions in patients undergoing surgery.
- Trial name
- NCT03202472
- Testing
- Implanted Medical Device, Mammography, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Secondarily Infected Traumatic Skin Lesions
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions
To compare the safety and efficacy of Perrigo's product to an FDA approved product, and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions
- Trial name
- NCT04155203
- Testing
- Mupirocin Calcium, Vehicle
- Where
- United States
- Volunteers
- 657 people
- Sponsor
- Padagis LLC
Acne Vulgaris
Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris
The primary objectives of the study is to show CD2475/101 40mg tablets taken once a day for 16 weeks is superior to the placebo in Change from baseline to Week 16(Last Observation Carry Forward, Intent To Treat) in inflammatory…
- Trial name
- NCT01320033
- Testing
- CD2475/101 40 mg, Doxycycline 100 mg
- Where
- 31 sites in United States
- Volunteers
- 662 people
- Sponsor
- Galderma R&D